Correction to Inspector Appointment Disclosure: Addition of Plaintiffs


  • Enzychem Lifesciences filed a corrected disclosure on July 23, 2026, modifying the plaintiffs/applicants to Nam OOO and two others regarding the court decision to appoint an inspector received on July 22, 2026.
  • The correction reaffirms the court's appointment of lawyer Kwon Jongwon as inspector to examine the legality of the extraordinary general meeting scheduled for July 23, 2026, related to a management dispute, with the company bearing the inspector remuneration of 5.5 million won.
  • Beyond the addition of plaintiffs, the substance of the inspector appointment remains unchanged, so management uncertainty persists but the correction has limited direct impact on shareholder value.
  • [AI Summary]This amendment is a clerical correction with no financial shock, confirming procedural progress with the inspector appointment. While short-term stock volatility due to the management dispute remains possible, the unchanged terms and schedule warrant a neutral stance.

KOSDAQ Filing Information


  • [Correction of Description] Judgment/Decision on Lawsuit, etc. (Management Rights Dispute Lawsuit) (Appointment of Inspector)
  • Company: Enzychem Lifesciences (183490)
  • Submission: Enzychem Lifesciences Corporation
  • Under KRX KOSDAQ Market Division

  • Shares: 84,640,235
  • Price: 990 KRW
  • Market Cap: 83.8 B KRW